

EU Lead Factory awards screening program to CELLIPSE

Grenoble and Lyon, March 18 2015. CELLIPSE was awarded an exclusive High Throughput Screening research program to screen the [EU Lead Factory](#)'s (ELF) joint compound library on an undisclosed innovative therapeutic target, by the Selection Committee on January 19 2015. The kick-off meeting was held in mid-February and the effort, led by Dr Renaud Prudent from CELLIPSE and Dr Helma Rutjes from the ELF partner [Pivot Park Screening Centre](#), is expected to yield its first results within 9 months.

"We are delighted to be selected for the ELF screening initiative as it gives CELLIPSE the promise of high quality hits from ELF's current >350,000-compound strong chemical library to develop potential first-in-class therapies against our target. Also, these chemical assets will be highly complementary to the ones that we are currently developing in house for leukemia." stated Dr Prudent, Chief Operating Officer of CELLIPSE. "This gives us a fantastic opportunity, if we are successful, to partner with leading European pharmaceutical companies such as Bayer, Sanofi, Janssen, Merck, AstraZeneca, Lundbeck or UCB who are providing their chemical assets to the ELF initiative" added Fabrice Paublant, CELLIPSE's CEO.

About EU Lead Factory (ELF): ELF is a unique public-private partnership that promotes new discoveries via open innovation and crowdsourcing. It is designed to provide best-in-class resources and funding-in-kind, to academics or SMEs who are working on promising biology targets or chemistry scaffolds. It is financed jointly by the Innovative Medicine Initiative from FP7 EU Grants Programme and EFPIA companies' in kind contribution. To know more about EU Lead Factory, please visit www.europeanleadfactory.eu

About CELLIPSE: CELLIPSE is a drug discovery company with its Research facilities based in Grenoble, France, dedicated to bringing innovative targeted therapies to patients and healthcare professionals. CELLIPSE is developing a pipeline of small molecules targeting the cytoskeleton (i.e. microtubules and actin filaments) based on its proprietary « cell to drug discovery » approach.

For all inquiries and further information, please contact CELLIPSE at contact@cellipse.com or visit www.cellipse.com.